Potential mechanisms underlying the inhibitory effects of magnesium on vascular calcification
Overview of the potential mechanisms underlying the inhibitory effects of magnesium on vascular calcification. In chronic kidney disease (CKD), imbalances in calcification inhibitors and inducers promote the formation of amorphous calcium/phosphate particles (ACPs). These particles nucleate and mature into hydroxyapatite crystals, which are crucial for the osteogenic differentiation of vascular smooth muscle cells (VSMC). Mg demonstrates inhibitory effects on hydroxyapatite formation, and studies suggest it also hinders vascular calcification by influencing the maturation of calciprotein particles 2 (CPP2), which also induces the transformation of VSMCs into an osteogenic phenotype, ultimately contributing to vascular calcification. In addition, since CPP2 consists of a crystalline hydroxyapatite core, it is possible that the prevention of hydroxyapatite crystal formation by Mg might also contribute, at least in part, to its effects on CPP2-mediated vascular calcification. The anti-calcifying effects of Mg also involve decreased expression of osteogenic transcription factors and the prevention of the loss of calcification inhibitors. Mechanistically, the divalent cation channel transient receptor potential melastatin 7 (TRPM7), a major Mg channel in VSMCs, plays an important role in the development of calcification. Mg uptake by TRPM7 inhibits the Wnt/β-catenin signaling pathway, which is known to regulate genes promoting VSMC osteogenic differentiation. Additionally, Mg prevents high phosphate-induced VSMC osteogenic differentiation by activating the calcium-sensing receptor (CaSR), which acts as a calcimimetic to reduce vascular calcification. MicroRNA modulation is another potential mechanism, with Mg counteracting the disrupted expression of specific microRNAs (i.e., 30b, 133a, and 143) promoted by high phosphate levels, contributing to the inhibition of vascular calcification